Mitomycin C – an overview | ScienceDirect Topics, Mitomycin C – Wikipedia, Mitomycin C (MMC) is the best investigated subtype. It serves as a prototype for drugs with bioreductive alkylation, which is a unique feature of this class. MMC is mainly active under anaerobic circumstances. The pharmacokinetics are linear in a two-compartment model.
11/1/1990 · Mitomycin C (MMC) is an alkylating antibiotic derived from Streptomyces caespitosus that prevents fibrosis and collagen deposition by inhibiting DNA synthesis. Several studies in non-lung…
Mitomycin C inhibits DNA synthesis and cross-links DNA at the N6 position of adenine and at the O6 and N2 positions of guanine. In addition, single-strand breakage of DNA is caused by reduced mitomycin C (this can be prevented by free radical scavengers). Its action is most prominent during the late G1 and early S phases of the cell cycle.
Mechanism of action The activation of Mitomycin-C begins with the reduction of the quinone structure. One-electron reduction is mediated by cytochrome P-450 reductase, xanthine oxidase, cytochrome b5 reductase, etc.
and two-electron reduction is mediated by DT-diaphorase, xanthine dehydrogenase, etc. 1.
Alkylation of DNA is the most favored mechanism of action … Mitomycin C (MMC) is a chemotherapeutic drug that requires an enzymatic bioreduction to exert its biological effects. Upon reduction, MMC is converted into a highly reactive bis-electrophilic intermediate that alkylates cellular nucleophiles.
10/1/1990 · title = Mitomycin C: mechanism of action, usefulness and limitations.
abstract = The mitomycins are antitumor antibiotics that are under investigation now for more than 30 years. Mitomycin C (MMC) is the best investigated subtype. It serves as a prototype for drugs with bioreductive alkylation, which is a unique feature of this class.
